ArticleProceedings of the National Academy of Sciences of the United States of America2009
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 53 citations in OpenAlex.
- Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.European journal of nuclear medicine and molecular imaging · 2011Trial
- Interpretable Multi-Cancer Early Detection Using SHAP-Based Machine Learning on Tumor-Educated Platelet RNA.Diagnostics (Basel, Switzerland) · 2025Article
- Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer.Cold Spring Harbor perspectives in medicine · 2021Review
- Predicting Gemcitabine Delivery byJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Molecular Imaging of Deoxycytidine Kinase Activity Using Deoxycytidine-Enhanced CEST MRI.Cancer research · 2019Article
- Translational molecular imaging in exocrine pancreatic cancer.European journal of nuclear medicine and molecular imaging · 2018Review
- 4-N-Alkanoyl and 4-N-alkyl gemcitabine analogues with NOTA chelators for 68-gallium labelling.Bioorganic & medicinal chemistry · 2018Article
- Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.Advanced drug delivery reviews · 2018Review
- The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application toEuropean journal of medicinal chemistry · 2018Article
- TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC).PloS one · 2018Article
- Imaging Cancer Metabolism.Biomolecules & therapeutics · 2018Review
- In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.Molecular imaging and biology · 2017Article
- Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.Cell chemical biology · 2016Article
- [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Advances in PET Detection of the Antitumor T Cell Response.Advances in immunology · 2016Review
- PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.European journal of nuclear medicine and molecular imaging · 2015Article
- INDs for PET molecular imaging probes-approach by an academic institution.Molecular imaging and biology · 2014Article
- Synthesis and cytostatic evaluation of 4-N-alkanoyl and 4-N-alkyl gemcitabine analogues.Journal of medicinal chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Gemcitabine (2',2'-difluorodeoxycytidine, dFdC) and cytosine arabinoside (cytarabine, ara-C) represent a class of nucleoside analogs used in cancer chemotherapy. Administered as prodrugs, dFdC and ara-C are transported across cell membranes and are converted to cytotoxic derivatives through consecutive phosphorylation steps catalyzed by endogenous nucleoside kinases. Deoxycytidine kinase (DCK) controls the rate-limiting step in the activation cascade of dFdC and ara-C. DCK activity varies significantly among individuals and across different tumor types and is a critical determinant of tumor responses to these prodrugs. Current assays to measure DCK expression and activity require biopsy samples and are prone to sampling errors. Noninvasive methods that can detect DCK activity in tumor lesions throughout the body could circumvent these limitations. Here, we demonstrate an approach to detecting DCK activity in vivo by using positron emission tomography (PET) and (18)F-labeled 1-(2'-deoxy-2'-fluoroarabinofuranosyl) cytosine] ([(18)F]FAC), a PET probe recently developed by our group. We show that [(18)F]FAC is a DCK substrate with an affinity similar to that of dFdC. In vitro, accumulation of [(18)F]FAC in murine and human leukemia cell lines is critically dependent on DCK activity and correlates with dFdC sensitivity. In mice, [(18)F]FAC accumulates selectively in DCK-positive vs. DCK-negative tumors, and [(18)F]FAC microPET scans can predict responses to dFdC. We suggest that [(18)F]FAC PET might be useful for guiding treatment decisions in certain cancers by enabling individualized chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.